BIND Biosciences Appoints Industry Veteran Daniel Lynch as Chairman of the Board of Directors

BIND Biosciences Appoints Industry Veteran Daniel Lynch as Chairman of the Board of Directors

September 20, 2012

CAMBRIDGE, Mass., Sep 20, 2012 (BUSINESS WIRE) -- BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins(TM), today announced the appointment of Daniel S. Lynch as Chairman of the company's board of directors.

"Dan has a twenty-five year track record of building outstanding biotechnology and pharmaceutical companies. He brings with him a depth of industry expertise and a global business view that will serve us well as we move toward achieving a number of aggressive milestones including the initiation of the Phase 2 clinical trials of BIND-014, our lead Accurin for treatment of solid tumors, and positioning the company for long-term growth," said Scott Minick, President and Chief Executive Officer of BIND Biosciences. "Dan's clear focus on the patient is well aligned with BIND's strategy. We look forward to working with Dan to maximize the benefits of our technology and products for patients and shareholders."

"BIND is poised to significantly improve patient outcomes with its pipeline of novel Accurins, which have already shown strong clinical data as a potential to become important drugs in oncology, with future opportunities in inflammatory diseases and cardiovascular disorders," said Mr. Lynch. "BIND is leading the translation of nanomedicine innovations from the laboratory toward commercialization, and will have major impact on the treatment of disease. BIND's technology platform uniquely enables a pipeline of best-in-class drugs that will position the company well as it charts its growth into a multi-billion dollar organization. I look forward to working with BIND's management team and board members to maximize the potential value inherent in the company's unique platform and its lead Accurin drug candidate, BIND-014, for the treatment of solid tumors."

Dan Lynch brings more than 25 years of experience serving in management and board positions in the biotechnology and pharmaceutical industries. Dan spent nearly five years at ImClone Systems, serving as chief executive officer and chief financial officer. As CEO, he led ImClone through a significant turnaround, including securing FDA approval of ERBITUX(R) (Cetuximab), an important new cancer treatment. As CFO, Dan led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He served on the board of directors and the audit committee of U.S. Oncology, Inc. for five years until December, 2010, when it was acquired by McKesson. More recently Dan was Executive Chairman of the board for Avila Therapeutics and Stromedix. In addition to BIND Biosciences, Dan is currently a member of the board of directors for bluebird bio, Edimer Pharmaceuticals, and Ember Therapeutics. Dan received his BA in Mathematics from Wesleyan University and his MBA from the Darden Graduate School of Business Administration at the University of Virginia.

About BIND Biosciences

BIND Biosciences is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins(TM). BIND's Medicinal Nanoengineering(TM) platform enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.

BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best-in-class drugs and improve patient outcomes in the areas of oncology, inflammatory diseases and cardiovascular disorders. BIND's lead product candidate, BIND-014, is currently in Phase 1 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors. BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products.

BIND is backed by leading investors, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments, EndeavourVision and Rusnano. BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine, Professors Robert Langer, David H. Koch Institute Professor of the Massachusetts Institute of Technology (MIT) and Omid Farokhzad, Associate Professor of Harvard Medical School. For more information, please visit the company's web site at www.bindbio.com.

SOURCE: BIND Biosciences


        
        The Yates Network 
        Gina Nugent, 617-460-3579